Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 4/20 | 0.78 |
| ▸ | CCR2 | P41597 | 10/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592778 | 0.89 | ABCB11 (0.61) | ABCB11CCR2MAPTPKMGAA | |
| SCHEMBL6599243 | 0.88 | ABCB11 (1.00) | ABCB11CCR2MAPTPKMGAA | |
| SCHEMBL7084277 | 0.85 | ABCB11 (0.63) | ABCB11CCR2 | |
| SCHEMBL7086963 | 0.77 | ABCB11 (0.55) | ABCB11CCR2MAPTPKMGAA | |
| SCHEMBL21465476 | 0.76 | ABCB11 (0.68) | ABCB11CCR2MAPTPKMALDH1A1 | |
| SCHEMBL6599266 | 0.76 | ABCB11 (0.77) | ABCB11CCR2MAPTPKMGAA | |
| SCHEMBL7083553 | 0.76 | ABCB11 (0.51) | ABCB11CCR2MAPTPKMGAA | |
| SCHEMBL7082850 | 0.75 | ABCB11 (1.00) | ABCB11CCR2 | |
| SCHEMBL7086771 | 0.74 | ABCB11 (0.48) | ABCB11CCR2MAPTLMNAMEN1 | |
| SCHEMBL7089675 | 0.73 | ABCB11 (0.48) | ABCB11CCR2MAPTPKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |
| EP-1252142-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-10-30 | — | — | EP | claimed |
| WO-2001051466-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | claimed |
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | CCR2, CCR1, CCR5 | ABCB11 391/4885CCR2 1/4885MAPT 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.